Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Molecules ; 27(11)2022 Jun 02.
Artigo em Inglês | MEDLINE | ID: mdl-35684505

RESUMO

The in vitro antiproliferative activity of a phenolic-rich extract from Lycium barbarum fruits against head and neck HPV16 squamous cell carcinoma (OSCC) has been demonstrated, indicating for the first time that L. barbarum extract inhibits human papillomavirus (HPV) type 16 cell lines. Ethanol extract of L. barbarum was used for cell viability evaluation on SCC090, CAL27, and HGnF cell lines. After 24 and 48 h, the cell cycle effect of L. barbarum extract (at 1.0, 10, and 100 µg/mL) was measured via flow cytometry. In addition, the mRNA expression on E6/E7 and p53 via RT-PCR and the expression of p16, p53, Ki-67, and Bcl-2 via immunohistochemistry were also determined. Untreated cells, 20 µM cisplatin, and a Camellia sinensis-derived extract were used as negative and positive controls, respectively. We demonstrated that the studied L. barbarum extract resulted in G0/G1 arrest and S phase accumulation in SCC090 at 1.0 and 10 µg/mL. A reduction in mRNA levels of E6/E7 oncogenes (p < 0.05) with p53 overexpression was also observed through PCR, while immunohistochemical analyses indicated p16 overexpression (p > 0.05) and a decrease in p53 overexpression. The observed effects were associated with anticancer and immunomodulatory phenolics, such as flavonols/flavan-3-ols and tyramine-conjugated hydroxycinnamic acid amides, identified in the studied extract. These findings revealed that the phenolic-rich extract of L. barbarum fruits has promising properties to be considered further for developing new therapies against oral and oropharyngeal HPV lesions.


Assuntos
Neoplasias de Cabeça e Pescoço , Lycium , Proteínas Oncogênicas Virais , Infecções por Papillomavirus , Linhagem Celular , Frutas/química , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Papillomavirus Humano 16/genética , Humanos , Lycium/química , Proteínas E7 de Papillomavirus/análise , Proteínas E7 de Papillomavirus/genética , Proteínas E7 de Papillomavirus/metabolismo , Infecções por Papillomavirus/complicações , Fenóis/análise , Fenóis/farmacologia , Extratos Vegetais/análise , Extratos Vegetais/farmacologia , RNA Mensageiro , Proteínas Repressoras/genética , Carcinoma de Células Escamosas de Cabeça e Pescoço , Proteína Supressora de Tumor p53/genética , Proteína Supressora de Tumor p53/metabolismo
2.
J Oral Pathol Med ; 43(9): 685-90, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24761760

RESUMO

BACKGROUND: The scope of this work was to study synergism between human papillomavirus (HPV) infection and tobacco in vitro, both known to be independent risk factors for oral cancer. METHODS: HPV-positive and HPV-negative oral keratinocytes and oral HPV-negative fibroblasts were exposed to smokeless tobacco extract (STE) prepared from the Scandinavian (STE1) and US-type (STE2) snuff. Cell cycle profiles were determined with flow cytometry, and HPV E6/E7 mRNA expression in HPV-positive cells was assayed using RT-qPCR. RESULTS: The exposure of HPV-positive keratinocytes with STE2 increased the number of aneuploid cells from 27% to 80% of which 44% were in S-phase, while none of the diploid cells were in S-phase. The changes after STE1 exposure were less than seen after STE2: from 27% to 31% of which 34% were in S-phase. STE had no effect on HPV16 E6/E7 expression in HPV-positive keratinocytes. In oral spontaneously transformed, HPV-negative keratinocytes, the number of aneuploid cells at G2-M stage increased after STE1 and STE2 exposure from 3% to 9% and 7%, respectively. In HPV-negative oral fibroblasts, the number of cells at G2-M phase increased from 11% to 21% after STE1 and 29% after STE2 exposure. CONCLUSIONS: The effect of STE varied in the cell lines studied. STE2 increased significantly the proportion of aneuploid cells in HPV-positive oral keratinocytes, but not HPV16 E6/E7 expression. This indicates that tobacco products may enhance the effects of HPV 16 and the risk of DNA aneuploidy increasing risk to malignant transformation.


Assuntos
Aneugênicos/efeitos adversos , Aneuploidia , Transformação Celular Viral/fisiologia , Papillomavirus Humano 16/fisiologia , Queratinócitos/efeitos dos fármacos , Mucosa Bucal/efeitos dos fármacos , Extratos Vegetais/efeitos adversos , Tabaco sem Fumaça/efeitos adversos , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Linhagem Celular Transformada , Diploide , Fibroblastos/efeitos dos fármacos , Fibroblastos/virologia , Fase G2/efeitos dos fármacos , Gengiva/citologia , Gengiva/virologia , Humanos , Queratinócitos/virologia , Mucosa Bucal/citologia , Mucosa Bucal/virologia , Nicotina/efeitos adversos , Proteínas Oncogênicas Virais/análise , Proteínas Oncogênicas Virais/efeitos dos fármacos , Proteínas E7 de Papillomavirus/análise , Proteínas E7 de Papillomavirus/efeitos dos fármacos , Proteínas Repressoras/análise , Proteínas Repressoras/efeitos dos fármacos , Fase S/efeitos dos fármacos , Pele/citologia , Pele/virologia , Tetraploidia
3.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 27(6): 573-5, 2007 Jun.
Artigo em Chinês | MEDLINE | ID: mdl-17633379

RESUMO

Human papilloma virus (HPV) infection is closely correlated with the occurrence of cervical cancer and precancerous lesion, high risk HPV can induce cervical cancer by the corresponding protein of E6 and E7 gene expression. Earlier diagnosis and earlier prevention of HPV infection are the key points in blocking cervical cancer, and combined use of Chinese herbal preparations with Western medicine is the important way for preventing HPV infection and prohibiting cervical canceration. So, to develop anti-viral chemical compound from natural drugs has become the hotspot of research today.


Assuntos
Medicamentos de Ervas Chinesas/uso terapêutico , Interferons/uso terapêutico , Infecções por Papillomavirus/tratamento farmacológico , Neoplasias do Colo do Útero/tratamento farmacológico , Quimioterapia Combinada , Feminino , Humanos , Proteínas Oncogênicas Virais/análise , Proteínas E7 de Papillomavirus/análise , Fitoterapia , Proteínas Repressoras/análise , Neoplasias do Colo do Útero/virologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA